Strong Q4 Performance
Q4 saw a 7% revenue growth ex-antigen, strong growth in Imaging, Varian, and Advanced Therapies, and a 16% increase in adjusted EPS. Free cash flow more than doubled compared to Q4 last year.
Imaging Segment Success
Imaging grew by almost 8% with an adjusted EBIT margin of 24.2%, indicating a year-over-year margin expansion of 180 basis points.
Varian's Strong Finish
Varian achieved over EUR 1.1 billion in revenue with 10% growth against tough comps. The segment saw continuous sequential margin expansion.
Diagnostics Turnaround
Diagnostics achieved a margin expansion to 5% this quarter from 2% in the prior year, driven by the transformation program.
Free Cash Flow Improvement
Free cash flow increased by more than 60% to EUR 2.1 billion for the fiscal year, driven by higher earnings and improved inventory turns.